Hematology (all articles)
48-week follow-up of a RCT | Pegcetacoplan vs. Eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
8 Sep, 2022 | 14:29h | UTCPegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial – The Lancet Haematology (link to abstract – $ for full-text)
Original Study: Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria – New England Journal of Medicine
Commentary on Twitter (thread – click for more)
NEW research—Duration of improved haem outcomes and favourable safety over 48 weeks suggests that pegcetacoplan has the potential to alter treatment goals in patients with paroxysmal nocturnal haemoglobinuria: long-term results of PEGASUS #PNH https://t.co/dpT5cDih8X
— The Lancet Haematology (@TheLancetHaem) September 1, 2022
Opinion | Tranexamic acid for safer surgery: the time is now.
7 Sep, 2022 | 12:37h | UTCTranexamic acid for safer surgery: the time is now – British Journal of Surgery
Related:
Update on applications and limitations of perioperative tranexamic acid.
Review | Diagnosis and treatment of myelodysplastic syndromes.
7 Sep, 2022 | 12:33h | UTCDiagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA
Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.
7 Sep, 2022 | 12:29h | UTCClinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o
— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022
Brief Review | Thromboprophylaxis in critical care.
6 Sep, 2022 | 14:41h | UTCThromboprophylaxis in critical care – Intensive Care Medicine
Review | The use of whole blood transfusion in trauma.
6 Sep, 2022 | 14:15h | UTCThe Use of Whole Blood Transfusion in Trauma – Current Anesthesiology Reports
Systematic Review | Hydroxyurea for sickle cell disease.
5 Sep, 2022 | 14:14h | UTCHydroxyurea (hydroxycarbamide) for sickle cell disease – Cochrane Library
Summary: Hydroxyurea (also known as hydroxycarbamide) for people with sickle cell disease – Cochrane Library
Systematic Review | The effect of heparin and its preparations on disseminated intravascular coagulation mortality and hospitalization.
1 Sep, 2022 | 11:34h | UTC
Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.
31 Aug, 2022 | 11:32h | UTCCommentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network
#ESCCongress | In critically ill patients with COVID-19, full-dose anticoagulation reduced thrombotic events but increased the risk of bleeding.
30 Aug, 2022 | 12:12h | UTCNews Release: Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients – European Society of Cardiology
Related:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In the #COVID-PACT 2×2 factorial RCT, full-dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications but w/ increased bleeding among critically-ill patients w/ COVID-19 https://t.co/UNxFCIC5B9 pic.twitter.com/p5LGmpCGeL
— Circulation (@CircAHA) August 29, 2022
#ESCCongress – RCT | In patients with rheumatic heart disease–associated atrial fibrillation, treatment with a Vitamin K antagonist led to a lower rate of cardiovascular events or death compared to Rivaroxaban.
29 Aug, 2022 | 12:33h | UTCRivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Trial backs standard of care for rheumatic heart disease and atrial fibrillation – European Society of Cardiology
Commentary: INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF – TCTMD
Commentary on Twitter
INVICTUS: In patients with RHD-associated AF, compared to rivaroxaban, VKA reduced cardiovascular events and mortality without increasing bleeding. #ESCCongress https://t.co/4C45LmmB5o pic.twitter.com/9n3OelzZvp
— NEJM (@NEJM) August 28, 2022
Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.
26 Aug, 2022 | 13:05h | UTCSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.
26 Aug, 2022 | 13:03h | UTCCommentaries:
Commentary on Twitter
6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Review | Blood transfusion reactions.
23 Aug, 2022 | 12:50h | UTC
Single-arm phase 2 study | Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent alpha-thalassaemia or beta-thalassaemia.
18 Aug, 2022 | 12:40h | UTCSafety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study – The Lancet (link to abstract – $ for full-text)
Commentary: PK Modulator Shows Promise in Thalassemia — In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients – MedPage Today (free registration required)
Guideline | Use of COVID-19 convalescent plasma.
17 Aug, 2022 | 14:28h | UTC
M-A | Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients.
15 Aug, 2022 | 12:27h | UTCRelated:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Review | Plasma exchange in the intensive care unit.
15 Aug, 2022 | 12:19h | UTCPlasma exchange in the intensive care unit: a narrative review – Intensive Care Medicine
Commentary on Twitter
Therapeutic plasma exchange in #ICU
? indications for urgent TPE
? mechanisms, kinetics and therapeutic goals
? diagnostic workup & monitoring
? technical aspects
? clinical response & complications
? unanswered questions & research agenda#FOAMcc
? https://t.co/CojkcA81Dy pic.twitter.com/MsAdjgJhNL— Intensive Care Medicine (@yourICM) August 13, 2022
M-A | Interventions to reduce infections in patients with hematological malignancies.
15 Aug, 2022 | 11:51h | UTCCommentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC
Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.
15 Aug, 2022 | 11:46h | UTCOriginal Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
Consensus Guidance | Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis.
12 Aug, 2022 | 14:54h | UTC
RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.
11 Aug, 2022 | 12:04h | UTCLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Commentary on Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022
Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.
9 Aug, 2022 | 12:22h | UTCLong-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
? Combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with relapsed/refractory #MultipleMyeloma ➡️ https://t.co/TkPRcTKSxg #JCO #MMSM pic.twitter.com/0OZAJtTXF1
— Journal of Clinical Oncology (@JCO_ASCO) April 15, 2022
Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.
5 Aug, 2022 | 14:37h | UTC
Review | Thrombotic microangiopathy in children.
5 Aug, 2022 | 13:56h | UTCThrombotic microangiopathy in children – Pediatric Nephrology (if the link is paywalled, try this one)